Adverse events related to oral hormonal contraceptive use in undergraduate pharmacy students
a cross-sectional study
DOI:
https://doi.org/10.1590/s2175-97902022e21335Keywords:
Oral hormonal contraceptive, Adverse events, Pharmacovigilance, Students, Compounding pharmacyAbstract
We aimed to measure the prevalence of adverse events related to oral hormonal contraceptive (OHC) use and their associated factors in undergraduate pharmacy students. A cross-sectional study was conducted by using an online questionnaire for female students of the Faculty of Pharmaceutical Sciences of the University of São Paulo from July to August 2020. A descriptive analysis of the data was carried out, which was followed by determining the prevalence ratios to identify possible factors associated with adverse events resulting from OHC. A total of 269 valid responses were obtained, among which 50.2% (n = 135) of the students reported using OHC as a contraceptive method and 21.2% (n = 57) affirmed that they had at least one adverse event related to OHC use, which corresponds to 42.2% of those who had used OHC. The most common adverse event was headache (70.2%), and a period of less than one month was the most cited (49.1%). Only migraine comorbidity was associated with the occurrence of adverse events related to OHC. These findings reinforce the high incidence of adverse events among OHC users and the low rate of discontinuation due to these events. There is a need to provide more information on contraceptive methods to users, including its risks and contraindications.
Downloads
References
Almeida FB, Sousa NMM, Barros GL, Almeida FB, Farias PAM, Cabral SAAO. Avaliação do uso de anticoncepcionais de emergência entre estudantes universitários. REBES. 2015;5(3):49-55.
Alves AS, Lopes MHBM. Conhecimento, atitude e prática do uso de pílula e preservativo entre adolescentes universitários. Rev Bras Enferm. 2008;(61):11-7.
Arya R, Antonisamy B, Kumar S. Sample Size Estimation in Prevalence Studies. Indian J Pediatr. 2012;79(11):1482-8.
Bahamondes L, Pinho F, de Melo NR, Oliveira E, Bahamondes MV. Fatores associados à descontinuação do uso de anticoncepcionais orais combinados. Rev Bras Ginecol Obstet. 2011;33(6):303-9.
Barr N. Managing Adverse Effects of Hormonal Contraceptives. Am Fam Physician. 2010:15;82 (12):1499-506.
Borges AL, Fujimori E, Kuschnir MC, Chofakian CB, de Moraes AJ, Azevedo GD, et al. ERICA: sexual initiation and contraception in Brazilian adolescents. Rev Saude Publica. 2016;50(Suppl 1):15s.
Brasil. Lei n° 9.263, de 12 de Janeiro de 1996. Disponível em: Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l9263.htm Acesso em 13 de Novembro de 2019.
» http://www.planalto.gov.br/ccivil_03/leis/l9263.htm
Bryden PJ, Fletcher P. Knowledge of the risks and benefits associated with oral contraception in a university-aged sample of users and non-users. Contraception. 2001;63(4):223-7.
Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception . 2011;84(1):19-34.
Cabral NMMD, Rocha AT, Câmara PAD, Melo MCSC, Brandt CT. Prevalência dos efeitos colaterais pelo uso de anticoncepcionais orais em estudantes de medicina de uma instituição privada. An Fac Med Olinda. 2018;2(2):28.
Coetzee MH, Ngunyulu RN. Assessing the use of contraceptives by female undergraduate students in a selected higher educational institution in Gauteng. Curationis. 2015;38(2):1535.
Conselho Federal de Farmácia. Resolução nº 586 de 29 de Agosto de 2013. Disponível em: Disponível em: https://www.cff.org.br/userfiles/file/resolucoes/586.pdf Acesso em 04 de Outubro de 2020.
» https://www.cff.org.br/userfiles/file/resolucoes/586.pdf
de Melo NR. Estrogen-Free Oral Hormonal Contraception : Benefits of the Progestin-Only Pill. Women’s Health (Lond.). 2010;6(5):721-35.
do Nascimento Chofakian CB, Moreau C, Borges ALV, Dos Santos OA. Contraceptive discontinuation: frequency and associated factors among undergraduate women in Brazil. Reprod Health. 2019;16(1):131.
Dragoman MV. The combined oral contraceptive pill -- recent developments, risks and benefits. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):825-34.
Edwards R, Biriell C. Harmonization in pharmacovigilance. Drug Saf. 1994;10(2):93-102.
Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;(1):CD003987.
Instituto Brasileiro de Geografia e Estatística. IBGE. Brasil em Síntese. 2015. Disponível em: Disponível em: https://brasilemsintese.ibge.gov.br/populacao/taxas-de-fecundidade-total.html Acesso em 12 de Novembro de 2019.
» https://brasilemsintese.ibge.gov.br/populacao/taxas-de-fecundidade-total.html
Kakaiya R, Lopez LL, Nelson AL. Women’s perceptions of contraceptive efficacy and safety. Contracept Reprod Med. 2017;2:19.
Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005;193(3 Pt 1):636-49.
Magalhães A, Morato C, Santos G. Anticoncepcional oral como fator de risco para trombose em mulheres jovens. J Med Health Promot. 2017;2(4):681-91.
Moreau C, Trussell J, Gilbert F, Bouyer J. Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol. 2007;109(6):1277-85.
Moura ERF, Silva RM, Galvão MTG. Dinâmica do atendimento em planejamento familiar no Programa Saúde da Família no Brasil. Cad Saude Publica. 2007;23(4):961-70.
Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14(1):66.
Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217(1-2):255-61.
Organização Mundial da Saúde. OMS. Mulheres e Saúde Evidências de hoje agenda de amanhã. 2011. Disponível em: Disponível em: https://www.who.int/eportuguese/publications/Mulheres_Saude.pdf?ua=1 Acesso em 12 de Novembro de 2019.
» https://www.who.int/eportuguese/publications/Mulheres_Saude.pdf?ua=1
Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev . 2015;2015(8):CD011054.
Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol . 1998;179(3 Pt 1):577-82.
Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain . 2017;18(1):108.
Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol. 2010;62(4):319-29.
Silva ECF, Neto OHC. Consumo e conhecimento sobre contraceptivos orais combinados por estudantes de farmácia da Faculdade Ciências da Vida. Rev Bras Cienc Vida. 2017;5(4):1-17.
Siqueira TC, Sato MDO, Santiago RM. Reações adversas em usuárias de anticoncepcionais orais. Rev Eletr Farm. [Internet]. 2017;14(4):56-65.
Steckert APP, Nunes SF, Alano GM. Contraceptivos hormonais orais: utilização e fatores de risco em universitárias. Arq Catarin Med. 2016;45(1):78-92.
Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol . 2000;95(2):261-6.
United Nations, Department of Economic and Social Affairs, Population Division (2019). World Contraceptive Use 2019 (POP/DB/CP/Rev2019). Disponível em: Disponível em: https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2019.asp Acesso em 28 de Janeiro de 2020.
» https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2019.asp
Varallo FR, Guimarães SOP, Abjaude SAR, Mastroianni PC. Causas de subnotificação de eventos adversos a medicamentos por profissionais da saúde: revisão sistemática. Rev Esc Enferm. USP. 2014;48(4):739-47.
Vieira CS, Oliveira LCO, Silva de Sá MF. Hormônios femininos e hemostasia. Rev Bras Ginecol Obstet . 2007;29(10):538-47.
World Health Organization. WHO. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2020. Oslo; 2019. Available from: Available from: https://www.whocc.no/atc_ddd_index/ Acesso em 13 de Setembro de 2020.
» https://www.whocc.no/atc_ddd_index/
World Health Organization. WHO. Medical Eligibility Criteria for Contraceptive Use (5th edn). 2015. Disponível em Disponível em https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/ Acesso em 04 de outubro de 2020.
» https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
